S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
Pentagon forges new high-tech agreement with Australia, United Kingdom, aimed at countering China

Vaxcyte Stock Price, News & Analysis (NASDAQ:PCVX)

$53.81
+2.04 (+3.94%)
(As of 12/1/2023 ET)
Compare
Today's Range
$50.91
$53.94
50-Day Range
$45.35
$53.81
52-Week Range
$34.11
$54.97
Volume
599,416 shs
Average Volume
568,824 shs
Market Capitalization
$5.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.20

Vaxcyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19.3% Upside
$64.20 Price Target
Short Interest
Bearish
7.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Vaxcyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$4.56 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.31) to ($4.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.28 out of 5 stars

Medical Sector

916th out of 951 stocks

Biological Products, Except Diagnostic Industry

158th out of 160 stocks


PCVX stock logo

About Vaxcyte Stock (NASDAQ:PCVX)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Stock Price History

PCVX Stock News Headlines

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $736,350.00 in Stock
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
PCVX Jan 2024 45.000 put
Vaxcyte GAAP EPS of -$0.91
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$64.20
High Stock Price Target
$70.00
Low Stock Price Target
$58.00
Potential Upside/Downside
+19.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-223,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.74 per share

Miscellaneous

Free Float
91,728,000
Market Cap
$5.12 billion
Optionable
Not Optionable
Beta
0.88
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives















PCVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings
or view top-rated stocks.

What is Vaxcyte's stock price target for 2024?

5 equities research analysts have issued 12 month price targets for Vaxcyte's stock. Their PCVX share price targets range from $58.00 to $70.00. On average, they anticipate the company's share price to reach $64.20 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for PCVX
or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2023?

Vaxcyte's stock was trading at $47.95 on January 1st, 2023. Since then, PCVX stock has increased by 12.2% and is now trading at $53.81.
View the best growth stocks for 2023 here
.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our PCVX earnings forecast
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) issued its earnings results on Monday, November, 6th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.07.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.79%), Wellington Management Group LLP (4.83%), Fred Alger Management LLC (2.20%), Jennison Associates LLC (1.87%), Braidwell LP (1.70%) and Kynam Capital Management LP (1.37%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman, Paul Sauer and Robert Lorne Hopfner.
View institutional ownership trends
.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PCVX) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -